drugset / Trial / NCT03510208
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Phase 1/2
Recruiting
46 enrolled
Stanford University
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Timeline
- Start
- 2018-05-16
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 50 mg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 100 mg | Intravenous |